Hoffmann-La Roche and Fresenius Kabi side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Hoffmann-La Roche | Fresenius Kabi |
|---|---|---|
| Phase 1 | Hoffmann-La Roche: 33 of its 80 programs at phase 1
and 28 more — sign in to see them all | 00% |
| Phase 2 | Hoffmann-La Roche: 18 of its 80 programs at phase 2
and 13 more — sign in to see them all | 00% |
| Phase 3 | Hoffmann-La Roche: 22 of its 80 programs at phase 3
and 17 more — sign in to see them all | Fresenius Kabi: 1 of its 1 programs at phase 3
|
| Approved, new studies | Hoffmann-La Roche: 7 of its 80 programs at approved, new studies
and 2 more — sign in to see them all | 00% |
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hoffmann-La Roche28 readouts · 7 phase 3 | Hoffmann-La Roche, Nov ’26: 4 programs whose next study reaches primary completion, 1 in phase 3
| Hoffmann-La Roche, Dec ’26: 4 programs whose next study reaches primary completion
| Hoffmann-La Roche, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Hoffmann-La Roche, Feb ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Hoffmann-La Roche, Mar ’27: 4 programs whose next study reaches primary completion
| Hoffmann-La Roche, Apr ’27: 3 programs whose next study reaches primary completion, 2 in phase 3
| Hoffmann-La Roche, May ’27: 1 program whose next study reaches primary completion
| Hoffmann-La Roche, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3
| Hoffmann-La Roche, Jul ’27: 2 programs whose next study reaches primary completion
| Hoffmann-La Roche, Aug ’27: 2 programs whose next study reaches primary completion
| Hoffmann-La Roche, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Hoffmann-La Roche, Oct ’27: 1 program whose next study reaches primary completion
|
| Fresenius Kabi1 readouts · 1 phase 3 | · | · | · | · | · | Fresenius Kabi, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| · | · | · | · | · | · |
Changed in the last 90 days
Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Hoffmann-La Roche
New programs 5
- RO7836748phase 1 · first study · Oct 23
- RO7821657phase 1 · first study · Oct 14
- RO7965032phase 2 · first study · Sep 25 · Geographic Atrophy
- RO7830698phase 2 · first study · Sep 11 · Pulmonary Disease, Chronic Obstructive
- RO7568282phase 2 · first study · Aug 20 · Parkinson Disease
Reached a new phase 1
- petrelintidephase 3 · Sep 11 · Obesity
Study stopped 1
- RO7763505phase 1 · terminated Nov 17 · none of its studies left running“The development of RO7763505 for coronary artery disease has been discontinued.” · NCT07495813
Primary completion later 11
- cevostamabphase 3 · Oct 2028 → Nov 2028 (+1 mo) · moved Nov 18 · NCT07555938
- emicizumabphase 3 · Apr 2027 → Oct 2027 (+5 mo) · moved Nov 16 · NCT06998524
- mosunetuzumabphase 2 · Feb 2028 → Aug 2028 (+5 mo) · moved Nov 16 · NCT07598396
- inavolisibphase 3 · Dec 2026 → May 2027 (+4 mo) · moved Nov 13 · NCT05894239
- glofitamabphase 2 · Jan 2027 → Jul 2029 (+30 mo) · moved Nov 10 · NCT06806033
- sefaxersenphase 3 · Aug 2026 → May 2028 (+21 mo) · moved Oct 5 · NCT05797610
+5 more
- giredestrantphase 3 · Dec 2027 → Jun 2028 (+5 mo) · moved Oct 2 · NCT05296798
- hyaluronidase (human recombinant)phase 3 · Dec 2027 → Jun 2028 (+5 mo) · moved Oct 2 · NCT05296798
- tifeglipronphase 2 · Nov 2026 → Feb 2028 (+14 mo) · moved Oct 1 · NCT07112872
- giredestrantphase 3 · Oct 2027 → Dec 2027 (+2 mo) · moved Sep 29 · NCT05296798
- hyaluronidase (human recombinant)phase 3 · Oct 2027 → Dec 2027 (+2 mo) · moved Sep 29 · NCT05296798
Fresenius Kabi
New programs 0
None
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 0
None
Where they overlap
Conditions where at least two of them have programs: 1 in all. A program counts in each condition its studies name most.
| Condition | Hoffmann-La Roche | Fresenius Kabi |
|---|---|---|
| Neoplasm Metastasisboth · compare here | Hoffmann-La Roche in Neoplasm Metastasis: 2 programs
Their studies: Hoffmann-La Roche’s studies of Neoplasm Metastasis in search | Fresenius Kabi in Neoplasm Metastasis: 1 program
Their studies: Fresenius Kabi’s studies of Neoplasm Metastasis in search |
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
No gene two of them both target, among the programs whose target is known.
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
- Programs a company names but has not registered are counted apart (Hoffmann-La Roche: 25).